Business Blockbuster - Helpng business to be more visible on Google
The Times Australia

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant glioma, which includes Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive childhood brain cancer.

Key Points

  • Orphan Drug Designation (ODD) is a special status accorded to drugs which are considered promising potential treatments for rare ('orphan') diseases, generally defined as those which affect less than 200,000 cases per annum in the United States
  • ODD can provide drug developers with up to seven years of Orphan Drug Exclusivity (ODE), extending the effective life of a commercial product. It also provides opportunities for grant funding, protocol assistance, and financial benefits, such as a waiver of New Drug Application fees, and tax credits
  • Receipt of ODD follows award of Rare Pediatric Disease Designation (RPDD) for DIPG on 7 August 2020

Kazia CEO, Dr James Garner, commented, "Taken together, RPDD and ODD provide a powerful suite of incentives, opportunities, and protections for the development of paxalisib in DIPG. We look forward to seeing initial data from the ongoing phase I study in DIPG at St Jude Children's Research Hospital during the second half of calendar 2020. In parallel, we are working closely with collaborators, advisors, and researchers to determine the best path forward for paxalisib in this devastating disease."

He added, "This award of ODD concludes a program of regulatory optimisation that Kazia has initiated for paxalisib over the past six months. As we orient paxalisib towards commercialization, these special designations from FDA will allow us to move forward in the swiftest and most effective way possible."

Orphan Drug Designation

ODD exists to recognise the development of a drug for a rare disease, which may affect adults or children. ODD provides an additional period of 7.5 years data exclusivity (for a paediatric disease), which allows companies to better defend their products against competition. It also results in a waiver by FDA of fees for a marketing application, under the Prescription Drug User Fees Act (PDUFA fees), which are just under US$ 3 million in FY2020. In addition, drugs with ODD may be eligible for orphan grants by FDA.

Kazia previously received ODD for paxalisib in glioblastoma in February 2018.

Summary of Paxalisib Regulatory Status

Glioblastoma

Most common and most aggressive adult brain cancer

DIPG

Highly aggressive childhood brain cancer

Orphan Designation

February 2018

August 2020

Fast Track Designation

August 2020

Rare Pediatric Disease Designation

n/a

August 2020

Next Steps

Kazia expects to present further data from its ongoing phase II study of paxalisib in glioblastoma at the Society for Neuro-Oncology (SNO) Annual Meeting in November 2020.

Initial efficacy data from the ongoing phase I study of paxalisib in DIPG at St Jude Children's Research Hospital is expected during 2H CY2020. Precise timing remains uncertain due to pandemic-related disruption in conference schedules, but Kazia expects to provide an update to investors at the earliest opportunity.

Paxalisib has been selected to join the international GBM AGILE pivotal study in glioblastoma, and recruitment is expected to begin in 2H CY2020.

Photo - https://photos.prnasia.com/prnh/20171120/1996749-1LOGO?lang=0[1]   

Read more https://www.prnasia.com/story/archive/3102015_AE02015_0

Business Times

Falling Premiums, Rising Risks: Why Australian Businesses Should …

Australian businesses are paying less for commercial insurance, even as the cost of settling claims continues to rise. This...

Choosing the Right Childcare for Your Family

Selecting the appropriate childcare for your family represents a significant decision, impacting both your child's developmen...

Give Customers an Update Time When the Job Time Is Uncertain

A customer has kept the afternoon free for a service visit. The business is still waiting to find out whether the previous jo...

Technology

What is a passkey — and should you …

Websites increasingly invite users to create a passkey. The unfamiliar name describes a simpler wa...

Local News

From paediatric nurse to trans-Tasm…

The time-honoured tradition of showing up with a home-cooked meal is getting a modern makeover, wi...

Culture

Head Injuries in Children and Adults: When Im…

Head injury scans are among the most time-critical imaging tests, and also among the most misunderst...

Travel

Jet Skis to Launch Surfers Skyward at Scarbor…

Twenty of WA's most exciting aerial surfers will be towed into waves at speed for Red Bull Aeriali...

The Times Features

Head Injuries in Children and Adults: When Imaging Is C…

Head injury scans are among the most time-critical imaging tests, and also among the most misunderst...

Kinder Unwraps Christmas 2026 with Personalised Santa S…

This Christmas, Kinder is making the festive season even more magical with a range of delicious ch...

Jet Skis to Launch Surfers Skyward at Scarborough Beach

Twenty of WA's most exciting aerial surfers will be towed into waves at speed for Red Bull Aeriali...